Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909269 | 0.84 | ALDH1A1 (0.54) | PLA2G1BPLA2G2ALMNAALDH1A1MEN1 | |
| SCHEMBL12902739 | 0.81 | PLA2G1B (0.47) | PLA2G1BPLA2G2ALMNADNM1MEN1 | |
| SCHEMBL4169474 | 0.81 | PLA2G1B (0.43) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL21701072 | 0.80 | DNM1 (0.48) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL29324452 | 0.80 | PLA2G1B (0.46) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL15534875 | 0.79 | PLA2G1B (0.44) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL24127950 | 0.78 | DNM1 (0.58) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL24127943 | 0.78 | DNM1 (0.58) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL21899528 | 0.78 | DNM1 (0.58) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 | |
| SCHEMBL24127938 | 0.78 | DNM1 (0.58) | PLA2G1BPLA2G2ALMNADNM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250375-A1 | CIRCULAR RNA ENCODING CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA | ORNA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-4289951-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023056033-A1 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING CIRCULAR POLYNUCLEOTIDES | ORNA THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2022261490-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11357856-B2 | Lipids for delivery of active agents | Acuitas Therapeutics, Inc. (CA) | 2022-06-14 | — | — | US | disclosed |
| WO-2021226597-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021189059-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021030701-A1 | IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2021-02-18 | — | — | WO | disclosed |
| US-20200046838-A1 | LIPIDS FOR DELIVERY OF ACTIVE AGENTS | Acuitas Therapeutics, Inc. (CA) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | PLA2G1B 2346/4885PLA2G2A 1979/4885LMNA 918/4885 |
| US-20200046838-A1 | LIPIDS FOR DELIVERY OF ACTIVE AGENTS | SGMS1, PHOSPHO1, LRAT | PLA2G1B 89/4885PLA2G2A 43/4885LMNA 168/4885 |
| US-20230226096-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, HNRNPA1, HNRNPAB | PLA2G1B 2346/4885PLA2G2A 1979/4885LMNA 918/4885 |
| US-20230058784-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | RTCB, RNGTT, HNRNPAB | PLA2G1B 2195/4885PLA2G2A 1913/4885LMNA 1053/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | PLA2G1B 2346/4885PLA2G2A 1979/4885LMNA 918/4885 |
| US-11357856-B2 | Lipids for delivery of active agents | SGMS1, PHOSPHO1, LRAT | PLA2G1B 89/4885PLA2G2A 43/4885LMNA 168/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | PLA2G1B 2195/4885PLA2G2A 1913/4885LMNA 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.